证券日报网讯光大同创（301387）11月7日在互动平台回答投资者提问时表示，公司生产经营正常，股 票停牌需符合《深圳证券交易所创业板股票上市规则》等相关规定，公司未达到停牌条件。短期内公司 股价受二级市场波动、投资者预期和情绪等多重因素的影响而出现波动，公司管理层对此保持密切关 注。从长期来看，股价终将反映企业的内在价值，管理层对公司所在的行业和自身的业务前景依然充满 信心。 ...

Core Viewpoint - Company announced an investment of 20 million yuan in Dongguan Chenglin Electronics Co., Ltd., acquiring a 36.36% stake, which will make it a subsidiary included in the consolidated financial statements [1] Investment Details - The investment agreement was signed with Jiaxing Yidan Equity Investment Partnership and Peng Jia, with a cash investment totaling 20 million yuan [1] - The company will gain a capital contribution of 571.4286 thousand yuan in Dongguan Chenglin, corresponding to the 36.36% equity stake post-investment [1] Control Mechanism - A voting rights entrustment agreement was signed with existing shareholder Peng Jia, allowing the company to exercise voting rights for 30% of Dongguan Chenglin's shares [1] - This agreement ensures the company maintains control over Dongguan Chenglin following the investment [1] Strategic Focus - Dongguan Chenglin focuses on the new energy vehicle sector, providing functional materials and precision structural components [1] - The investment aims to enhance mutual empowerment and synergy, expanding the company's business layout in the new energy vehicle field [1] Business Integration - The company plans to effectively integrate and deeply bind customer resources through this investment [1] - The collaboration will also enable technology introduction and business synergy, enriching the product matrix and solutions in the consumer electronics sector [1]

Group 1 - The company has signed investment agreements to invest a total of 20 million RMB in Dongguan Chenglin Electronics Co., Ltd., acquiring a 36.36% stake in the company [1][2] - The investment will allow the company to control Dongguan Chenglin through a voting rights delegation agreement, enabling it to consolidate the subsidiary into its financial statements [1][2] - This strategic move is aimed at enhancing the company's capabilities in the new energy vehicle sector and improving its overall industry chain [2] Group 2 - The investment is expected to create a synergistic effect, allowing the company to integrate and deepen customer resource binding in the new energy vehicle market [2] - The company aims to leverage technology transfer and business collaboration to enhance its consumer electronics business and diversify its product offerings [2] - This investment is anticipated to positively impact the company's long-term competitive advantage in the market [2]

第二届董事会第十三次会议决议公告 证券代码：301387 证券简称：光大同创 公告编号：2025-076 深圳光大同创新材料股份有限公司 具体内容详见公司同日披露于中国证监会指定创业板信息披露网站巨潮资 讯网（www.cninfo.com.cn）的《关于对外投资的公告》。 表决结果：同意 8 票，反对 0 票，弃权 0 票。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 深圳光大同创新材料股份有限公司（以下简称"公司"）第二届董事会第 十三次会议于 2025 年 10 月 31 日上午 10：30 以通讯方式召开，本次会议通知 于 2025 年 10 月 29 日以邮件方式发出。本次会议由董事长马增龙先生主持，会 议应到会董事 8 人，实到 8 人，占公司董事总人数（8 人）的 100%。公司董事 会秘书列席了会议。会议的召集和召开符合《中华人民共和国公司法》及《深 圳光大同创新材料股份有限公司章程》的相关规定，合法有效。 二、董事会会议审议情况 （一）审议并通过了《关于公司对外投资的议案》 经公司董事会战略委员会审议通过，同意将本议 ...

（一）彭佳 证券代码：301387 证券简称：光大同创 公告编号：2025-077 深圳光大同创新材料股份有限公司 关于对外投资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、对外投资概述 深圳光大同创新材料股份有限公司（以下简称"公司"或"光大同创"） 于 2025 年 10 月 31 日与嘉兴市壹丹股权投资合伙企业（有限合伙）（以下简称 "嘉兴壹丹"）、彭佳等签署《关于东莞市承林电子有限公司之投资协议书》 （以下简称"《投资协议书》"）、《关于东莞市承林电子有限公司之股东协 议》（以下简称"《股东协议》"），公司以现金方式向东莞市承林电子有限 公司（以下简称"东莞承林"或"目标公司"）合计投资 2,000 万元人民币， 获得东莞承林 571.4286 万元的出资额，对应增资后东莞承林 36.36%的股权。同 时公司与东莞承林现有股东中的彭佳签署《表决权委托协议》，彭佳将其持有 的东莞承林 30%的股权对应的表决权等权利委托给公司行使，以实现公司对东 莞承林的控制。本次增资完成后，东莞承林将成为公司控股子公司，纳入公司 合并报表范围。 公司于 2 ...

经营业绩：营收行业第55，净利润第52 2025年三季度，光大同创营业收入11.59亿元，行业排名55/88，远低于行业第一名工业富联的6039.31亿元 和第二名立讯精密的2209.15亿元，也低于行业平均数154.93亿元和中位数14.15亿元；净利润3190.88万 元，行业排名52/88，与第一名工业富联的225.22亿元、第二名立讯精密的127.28亿元差距明显，低于行业 平均数6.35亿元和中位数5475.81万元。 资产负债率低于同业平均，毛利率高于同业平均 偿债能力方面，2025年三季度光大同创资产负债率为33.83%，低于行业平均的44.84%，较去年同期的 29.11%有所上升。从盈利能力看，当期毛利率为20.38%，高于行业平均的19.47%，但较去年同期的24.12% 有所下降。 董事长马增龙薪酬186.95万元，同比增加8.86万元 光大同创控股股东为深圳汇科智选投资有限合伙企业，实际控制人是马增龙。马增龙出生于1977年1月， 硕士学历，担任公司董事长兼总经理。2003年9月至2018年4月，他担任上海博琛包装材料厂总经理；2006 年8月至2018年9月，任惠州市光大园实业有限公 ...

Core Viewpoint - The company, Everbright Tongchuang (301387), reassured investors that its operations are proceeding normally and that stock price fluctuations are influenced by market conditions and investor preferences [1] Company Operations - The company emphasized that despite short-term stock price volatility, its core value remains unchanged [1] - The management is committed to improving operations and management practices to deliver better performance for shareholders [1]

Core Viewpoint - The company reported significant growth in both revenue and net profit for the first three quarters of 2025, indicating strong operational performance and financial health [1] Financial Performance - The company's operating revenue for the first three quarters reached 1.159 billion yuan, representing a year-on-year increase of 37.79% [1] - The net profit attributable to shareholders of the listed company was 28.1637 million yuan, showing a remarkable year-on-year growth of 279.94% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 25.4906 million yuan, which is a year-on-year increase of 125.80% [1] - The basic earnings per share stood at 0.2642 yuan [1]

Company Summary - Everbright Tongchuang (SZ 301387) announced on October 24 that it has recognized credit impairment losses and asset impairment losses amounting to 11.76 million yuan for the first three quarters of 2025, which will impact the total profit for the reporting period by the same amount [1] - As of the report, Everbright Tongchuang has a market capitalization of 4.4 billion yuan [1] Revenue Composition - For the first half of 2025, the revenue composition of Everbright Tongchuang is as follows: functional products account for 56.8%, protective products account for 40.54%, and others account for 2.65% [1]

Group 1 - The core point of the article is that Everbright Tongchuang (SZ 301387) held its 12th meeting of the second board on October 24, 2025, to review the proposal for the "2025 Q3 Report" [1] - For the first half of 2025, Everbright Tongchuang's revenue composition was as follows: functional products accounted for 56.8%, protective products accounted for 40.54%, and others accounted for 2.65% [1] - As of the report date, Everbright Tongchuang's market capitalization was 4.4 billion yuan [1] Group 2 - The article mentions that the Chinese innovative drug sector has sold overseas authorizations worth 80 billion USD this year [1] - There is a discussion on the hot secondary market for biomedicine, while the primary market is facing challenges in fundraising [1]